Skip to content

Study · Randomized controlled trial · 2010

5 results

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.

Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D

Primary care diabetes4 May 2010Cited by 15 (Europe PMC)

PMID20444662 (opens in a new tab)DOI10.1016/j.pcd.2010.04.001 (opens in a new tab)PepBankPUB-20444662
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, treatment satisfaction was higher with liraglutide with background metformin than with metformin alone.

    In plain wordsIn adults with type 2 diabetes, people on liraglutide were more satisfied with treatment than people on metformin alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseTreatment satisfaction versus metformin alone
    Study

    n: not reported in source

    Comparator
    Metformin alone
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients' treatment satisfaction on liraglutide was higher than with metformin alone and comparable with glimepiride+metformin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, treatment satisfaction with liraglutide was comparable with glimepiride with metformin.

    In plain wordsIn adults with type 2 diabetes, satisfaction with liraglutide was similar to satisfaction with glimepiride.

    Peptide
    Liraglutide
    Outcome
    No significant changeTreatment satisfaction versus glimepiride
    Study

    n: not reported in source

    Comparator
    Glimepiride plus metformin
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    comparable with glimepiride+metformin.
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, patients on liraglutide perceived lower frequency of hypoglycaemia than on glimepiride with metformin.

    In plain wordsIn adults with type 2 diabetes, people on liraglutide reported low blood sugar less often than people on glimepiride.

    Peptide
    Liraglutide
    Outcome
    DecreasePerceived frequency of hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Glimepiride plus metformin
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients perceived lower frequency of hypoglycaemia than glimepiride+metformin
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, patients on liraglutide perceived lower frequency of hyperglycaemia than on metformin.

    In plain wordsIn adults with type 2 diabetes, people on liraglutide reported high blood sugar less often than people on metformin alone.

    Peptide
    Liraglutide
    Outcome
    DecreasePerceived frequency of hyperglycaemia
    Study

    n: not reported in source

    Comparator
    Metformin alone
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and lower frequency of hyperglycaemia than metformin.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the impact of weight on quality of life did not differ between treatments.

    In plain wordsIn adults with type 2 diabetes, the effect of weight on quality of life did not differ between treatments.

    Peptide
    Liraglutide
    Outcome
    No significant changeImpact of weight on quality of life
    Study

    n: not reported in source

    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Impact of weight on quality of life did not differ.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.